181657 20230208173454.0 G:(EU-Grant)681103 681103 CORDIS G:(EU-Call)H2020-PHC-2015-single-stage_RTD H2020-PHC-2015-single-stage_RTD CORDIS corda__h2020::681103 originalID G:(EU-Grant)681103 BIOengineered grafts for Cartilage Healing In Patients (BIO-CHIP) 2015-11-01 - 2020-10-31 UNIVERSITAETSKLINIKUM FREIBURG UKLFR Germany http://www.uniklinik-freiburg.de/ip/splash/start.html CORDIS Istituto Ortopedico Gaetano Pini Istituto Ortopedico Gaetano Pini Italy http://www.gpini.it/ CORDIS ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK ECRIN France http://www.ecrin.org CORDIS MEDACTA INTERNATIONAL SA Switzerland http://www.medacta.ch CORDIS University of Basel University of Basel Switzerland https://www.unibas.ch/de CORDIS FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. Fraunhofer Germany http://www.fraunhofer.de CORDIS University of Zagreb University of Zagreb Croatia http://www.unizg.hr/ CORDIS University of Würzburg University of Würzburg Germany http://www.uni-wuerzburg.de/en/ueber/university/ CORDIS H2020-PHC-2015-single-stage_RTD 2015-11-01 2020-10-31 BIO-CHIP d 2015-11-01 - 2020-10-31 I:(DE-588b)5098525-5 European Union CORDIS Spontaneous healing of articular cartilage injuries is poor and untreated defects predispose to osteoarthritis. Current therapies, including innovative autologous cell-based treatments, cannot predictably and reproducibly restore cartilage structure and function. BIOCHIP will carry out a multicenter, prospective phase II clinical trial to treat knee cartilage injuries using engineered grafts based on autologous nasal chondrocytes (NC). As compared to typically employed articular chondrocytes, NC have a higher and more reproducible capacity to generate mature cartilage tissues. Importantly, molecular/mechanical characterization, large size animal studies and a phase I trial carried out by BIOCHIP partners have already shown the compatibility of NC upon implantation in a joint, with promising preliminary clinical results. BIO-CHIP’s specific objectives are: (1) To test the hypothesis that the maturation of NC-based cartilage grafts improves the clinical efficacy in the treatment of cartilage lesions (108 patients will be recruited to reach statistical significance) (2) To extend the range of clinical indications of NC-based grafts to so far untreatable pre-osteoarthritic lesions (‘kissing’ cartilage lesions in a sheep model) BIO-CHIP capitalizes on clinical experience of 4 reference centers for cartilage surgery, on established GMP manufacturing capacity and on preparation for commercial exploitation by a strong orthopedic device company. Demonstration of therapeutic efficacy of the new treatment will address a large clinical need (over 2 million cartilage defects/year worldwide), improve quality of life (reduce pain & disability in the young, delay prosthetic implants in the elderly), exploit a commercial opportunity (prospected revenues of up to 130 million €/year) and reduce healthcare costs (estimated 12,000€ healthcare savings/procedure). BIO-CHIP will consolidate the currently leading role of Europe in the development of cell-based cartilage regeneration strate oai:juser.fz-juelich.de:277240 authority:GRANT authority oai:dnet:corda__h2020::f68182f0d9f2375e95e95ce760db4b74 G CORDIS AUTHORITY oai:juser.fz-juelich.de:277240